½ÃÀ庸°í¼­
»óǰÄÚµå
1595271

ÀÓÇöõÆ® ÁÖÀ§¿° ½ÃÀå : À¯Çüº°, ÃÖÁ¾ »ç¿ëÀÚº° - ¼¼°è Àü¸Á(2025-2030³â)

Peri-implantitis Market by Type (Non-Surgical, Surgical), End-User (Dental Clinics, Hospitals) - Global Forecast 2025-2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: 360iResearch | ÆäÀÌÁö Á¤º¸: ¿µ¹® 181 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

ÀÓÇöõÆ® ÁÖÀ§¿° ½ÃÀåÀº 2023³â¿¡ 9¾ï 5,671¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú½À´Ï´Ù. 2024³â¿¡´Â 10¾ï 5,004¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, CAGR 9.84%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 18¾ï 4,654¸¸ ´Þ·¯¿¡ ´ÞÇÒ Àü¸ÁÀÔ´Ï´Ù.

ÀÓÇöõÆ® ÁÖÀ§¿°Àº Ä¡°ú ÀÓÇöõÆ® ÁÖº¯ Á¶Á÷¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â ¿°Áõ¼º ÁúȯÀ¸·Î, °í·ÉÈ­·Î ÀÎÇÑ ÀÓÇöõÆ® ½Ã¼ú Áõ°¡¿Í ±¸°­ °Ç°­¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁü¿¡ µû¶ó Ä¡°ú ºÐ¾ß¿¡ Å« µµÀüÀÌ µÇ°í ÀÖ½À´Ï´Ù. ±× Á¤ÀÇ´Â ÀÓÇöõÆ®ÀÇ ¾ÈÁ¤¼ºÀ» À§ÇùÇÏ´Â °ñ·® °¨¼Ò·Î À̾îÁö´Â ¿°ÁõÀÔ´Ï´Ù. ÀÓÇöõÆ® ÁÖÀ§¿°Àº ÀÓÇöõÆ® ¼ö¸íÀ» ¼Õ»ó½Ãų ¼ö Àֱ⠶§¹®¿¡ ÀÓÇöõÆ® ÁÖÀ§¿°¿¡ ´ëóÇÒ Çʿ伺ÀÌ ÀÖÀ¸¸ç, À̸¦ À§Çؼ­´Â °­·ÂÇÑ ¿¹¹æ, Áø´Ü ¹× Ä¡·á ¿ëµµÀÌ ÇÊ¿äÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ÀÀ¿ë ºÐ¾ß¿¡´Â Ç×±Õ ¿ä¹ý, ±â°è½Ä Å»ºÎÂø, Àç»ý ±â¼ú µîÀÌ Æ÷ÇԵ˴ϴÙ. ÃÖÁ¾ »ç¿ëÀÚ´Â Ä¡°ú, º´¿ø, ¿¬±¸±â°ü µî ´Ù¾çÇϸç, ÀÌ´Â ÇコÄɾî ȯ°æÀÇ ´Ù¾çÇÑ ¼ö¿ä¸¦ º¸¿©ÁÝ´Ï´Ù. ½ÃÀå ¼ºÀåÀº Ä¡°ú ±â¼úÀÇ ¹ßÀü, ½É¹ÌÀû Ä¡°ú ¼Ö·ç¼Ç¿¡ ´ëÇÑ È¯ÀÚµéÀÇ ¼±È£µµ Áõ°¡, ¿¬±¸°³¹ß¿¡ ´ëÇÑ ¸·´ëÇÑ ÅõÀÚ µîÀÇ ¿äÀο¡ ÀÇÇØ ¿µÇâÀ» ¹Þ½À´Ï´Ù. ƯÈ÷ Çõ½ÅÀûÀÎ Ä¡·á¹ý ¹× Àç»ý ¼Ö·ç¼Ç °³¹ß, À¯ÀüÀÚ ¹× ¹Ì»ý¹°ÇÐÀû Áö½ÄÀ» Ȱ¿ëÇÑ °³ÀÎ ¸ÂÃãÇü ÀÇ·á Á¢±Ù¹ý¿¡¼­ ºñÁî´Ï½º ±âȸ°¡ âÃâµÇ°í ÀÖ½À´Ï´Ù. Ä¡°ú ÀÇ·áÁøÀº ¶ÇÇÑ Á¶±â ¹ß°ßÀ» À§ÇÑ Ã·´Ü Áø´Ü µµ±¸¸¦ ¿ä±¸Çϰí ÀÖÀ¸¸ç, ÀÌ´Â ½ÃÀå È®´ë¸¦ À§ÇÑ ¼ºÀå Æ´»õ ½ÃÀåÀ» Á¦½ÃÇϰí ÀÖ½À´Ï´Ù. ±×·¯³ª ³ôÀº Ä¡·á ºñ¿ë, ºÒÃæºÐÇÑ º¸Çè Àû¿ë, Ç¥ÁØÈ­µÈ Ä¡·á ÇÁ·ÎÅäÄÝÀÇ ºÎÀç µîÀÌ ½ÃÀå È®»ê¿¡ °É¸²µ¹·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. ÀÓÇöõÆ® ÁÖÀ§¿°À» Á¤È®ÇÏ°Ô Áø´ÜÇϰí ÁøÇ༺ ÀÓÇöõÆ® ÁÖÀ§¿°À» È¿°úÀûÀ¸·Î Ä¡·áÇÏ´Â °ÍÀº º¹ÀâÇÑ ¹®Á¦ÀÔ´Ï´Ù. º¸´Ù ¹ÝÀÀ¼ºÀÌ ³ôÀº ÀÓÇöõÆ®¸¦ À§ÇÑ »ýüÀç·á °³¹ß, Ç×±Õ¼º Ç¥¸éÀ» °­È­ÇÏ´Â ³ª³ë±â¼ú, ¿¹Ãø Áø´ÜÀ» À§ÇÑ ¸Ó½Å·¯´× µîÀÇ ºÐ¾ß¿¡¼­ ±â¼ú Çõ½ÅÀÌ ¸Å¿ì Áß¿äÇÕ´Ï´Ù. ½ÃÀåÀÇ Æ¯¼ºÀº ¿©ÀüÈ÷ ¸Å¿ì ¿ªµ¿ÀûÀ̸ç, Ä¡°ú, »ý¸í°øÇÐ, Àç·á°úÇÐÀ» À¶ÇÕÇÑ ´ÙÇÐÁ¦Àû Çù¾÷¿¡ Å« ÀáÀç·ÂÀ» °¡Áö°í ÀÖ½À´Ï´Ù. ±â¾÷µéÀº Àü·«Àû ÆÄÆ®³Ê½Ê, °³¾÷ÀÇ¿¡ ´ëÇÑ Áö¼ÓÀûÀÎ ±³À°, ¿¬±¸°³¹ß¿¡ ´ëÇÑ ¸·´ëÇÑ ÅõÀÚ µî¿¡ ÁßÁ¡À» µÎ¾î ¿ìÀ§¸¦ À¯ÁöÇØ¾ß ÇÕ´Ï´Ù. ÀÌ·¯ÇÑ Â÷¿øÀ» Àß ±Øº¹ÇÏ¸é ½ÃÀå ħÅõ¸¦ ÅëÇØ ÀÓÇöõÆ® ÁÖÀ§¿° Ä¡·á ¼Ö·ç¼ÇÀÇ ÁÖµµ±ÇÀ» È®º¸ÇÒ ¼ö ÀÖÀ» °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.

ÁÖ¿ä ½ÃÀå Åë°è
±âÁØ ¿¬µµ(2023) 9¾ï 5,671¸¸ ´Þ·¯
¿¹Ãø ¿¬µµ(2024³â) 10¾ï 5,004¸¸ ´Þ·¯
¿¹Ãø ¿¬µµ(2030³â) 184¾ï 4,654¸¸ ´Þ·¯
CAGR(%) 9.84%

½ÃÀå ¿ªÇÐ: ºü¸£°Ô ÁøÈ­ÇÏ´Â ÀÓÇöõÆ® ÁÖÀ§¿° ½ÃÀåÀÇ ÁÖ¿ä ½ÃÀå ÀλçÀÌÆ® °ø°³

ÀÓÇöõÆ® ÁÖÀ§¿° ½ÃÀåÀº ¼ö¿ä ¹× °ø±ÞÀÇ ¿ªµ¿ÀûÀÎ »óÈ£ÀÛ¿ë¿¡ ÀÇÇØ º¯È­Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ½ÃÀå ¿ªÇÐÀÇ ÁøÈ­¸¦ ÀÌÇØÇÔÀ¸·Î½á ±â¾÷Àº Á¤º¸¿¡ ÀÔ°¢ÇÑ ÅõÀÚ °áÁ¤, Àü·«Àû ÀÇ»ç°áÁ¤, »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Æ÷ÂøÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Æ®·»µå¸¦ Á¾ÇÕÀûÀ¸·Î ÆÄ¾ÇÇÔÀ¸·Î½á ±â¾÷Àº Á¤Ä¡Àû, Áö¸®Àû, ±â¼úÀû, »çȸÀû, °æÁ¦Àû ¿µ¿ª¿¡ °ÉÄ£ ´Ù¾çÇÑ ¸®½ºÅ©¸¦ ¿ÏÈ­Çϰí, ¼ÒºñÀÚ Çൿ°ú ±×°ÍÀÌ Á¦Á¶ ºñ¿ë ¹× ±¸¸Å µ¿Çâ¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» º¸´Ù ¸íÈ®ÇÏ°Ô ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • ÀÓÇöõÆ® ÁÖÀ§¿°ÀÇ º¸±Þ·ü Áõ°¡
    • Èí¿¬ ¹× ´ç´¢º´ Àα¸ÀÇ ±Þ°ÝÇÑ Áõ°¡
    • ÀÓÇöõÆ® Áõ°¡¿¡ µû¸¥ ³ëÀÎ Àα¸ Áõ°¡
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ¼ö¼ú¿¡ ´ëÇÑ Áö½Ä ºÎÁ·°ú ºñ¿ë
  • ½ÃÀå ±âȸ
    • ·¹ÀÌÀú ¿À¿° Á¦°Å¿Í °°Àº ±â¼ú Çõ½Å°ú Áøº¸
  • ½ÃÀå °úÁ¦
    • ÀÓ»óÀû ÇѰè¿Í ±â´ÉÀû °úÁ¦

Portre's Five Forces: ÀÓÇöõÆ® ÁÖÀ§¿° ½ÃÀå °ø·«À» À§ÇÑ Àü·«Àû µµ±¸

Portre's Five Forces ÇÁ·¹ÀÓ¿öÅ©´Â ½ÃÀå »óȲ°æÀï ±¸µµ¸¦ ÀÌÇØÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. Portre's Five Forces ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÇ °æÀï·ÂÀ» Æò°¡Çϰí Àü·«Àû ±âȸ¸¦ Ž»öÇÒ ¼ö ÀÖ´Â ¸íÈ®ÇÑ ¹æ¹ýÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÌ ½ÃÀå ³» ¼¼·Âµµ¸¦ Æò°¡ÇÏ°í ½Å±Ô »ç¾÷ÀÇ ¼öÀͼºÀ» ÆÇ´ÜÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ÀÌ·¯ÇÑ ÅëÂû·ÂÀ» ÅëÇØ ±â¾÷Àº °­Á¡À» Ȱ¿ëÇϰí, ¾àÁ¡À» ÇØ°áÇϰí, ÀáÀçÀûÀÎ µµÀüÀ» ÇÇÇϰí, º¸´Ù °­·ÂÇÑ ½ÃÀå Æ÷Áö¼Å´×À» È®º¸ÇÒ ¼ö ÀÖ½À´Ï´Ù.

PESTLE ºÐ¼® : ÀÓÇöõÆ® ÁÖÀ§¿° ½ÃÀå¿¡¼­ÀÇ ¿ÜºÎ ¿µÇâ ÆÄ¾Ç

¿ÜºÎ °Å½Ã ȯ°æ ¿äÀÎÀº ÀÓÇöõÆ® ÁÖÀ§¿° ½ÃÀåÀÇ ¼º°ú ¿ªÇÐÀ» Çü¼ºÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. Á¤Ä¡Àû, °æÁ¦Àû, »çȸÀû, ±â¼úÀû, ¹ýÀû, ȯ°æÀû ¿äÀο¡ ´ëÇÑ ºÐ¼®Àº ÀÌ·¯ÇÑ ¿µÇâÀ» Ž»öÇÏ´Â µ¥ ÇÊ¿äÇÑ Á¤º¸¸¦ Á¦°øÇϸç, PESTLE ¿äÀÎÀ» Á¶»çÇÔÀ¸·Î½á ±â¾÷Àº ÀáÀçÀû À§Çè°ú ±âȸ¸¦ ´õ Àß ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ºÐ¼®À» ÅëÇØ ±â¾÷Àº ±ÔÁ¦, ¼ÒºñÀÚ ¼±È£µµ, °æÁ¦ µ¿ÇâÀÇ º¯È­¸¦ ¿¹ÃøÇÏ°í ¼±Á¦ÀûÀÌ°í ´Éµ¿ÀûÀÎ ÀÇ»ç°áÁ¤À» ³»¸± Áغñ¸¦ ÇÒ ¼ö ÀÖ½À´Ï´Ù.

½ÃÀå Á¡À¯À² ºÐ¼® ÀÓÇöõÆ® ÁÖÀ§¿° ½ÃÀå¿¡¼­°æÀï ±¸µµ ÆÄ¾Ç

ÀÓÇöõÆ® ÁÖÀ§¿° ½ÃÀåÀÇ »ó¼¼ÇÑ ½ÃÀå Á¡À¯À² ºÐ¼®À» ÅëÇØ °ø±Þ¾÷üÀÇ ¼º°ú¸¦ Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ±â¾÷Àº ¼öÀÍ, °í°´ ±â¹Ý, ¼ºÀå·ü°ú °°Àº ÁÖ¿ä ÁöÇ¥¸¦ ºñ±³ÇÏ¿© °æÀïÀû À§Ä¡¸¦ ÆÄ¾ÇÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ ºÐ¼®Àº ½ÃÀåÀÇ ÁýÁßÈ­, ´ÜÆíÈ­, ÅëÇÕÀÇ Ãß¼¼¸¦ ÆÄ¾ÇÇÒ ¼ö ÀÖÀ¸¸ç, °ø±Þ¾÷ü´Â Ä¡¿­ÇÑ °æÀï ¼Ó¿¡¼­ ÀÚ½ÅÀÇ ÀÔÁö¸¦ °­È­ÇÒ ¼ö ÀÖ´Â Àü·«Àû ÀÇ»ç°áÁ¤À» ³»¸®´Â µ¥ ÇÊ¿äÇÑ ÅëÂû·ÂÀ» ¾òÀ» ¼ö ÀÖ½À´Ï´Ù.

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º ÀÓÇöõÆ® ÁÖÀ§¿° ½ÃÀå¿¡¼­ÀÇ º¥´õ ¼º°ú Æò°¡

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º´Â ÀÓÇöõÆ® ÁÖÀ§¿° ½ÃÀå¿¡¼­ °ø±Þ¾÷ü¸¦ Æò°¡ÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. ÀÌ ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ºñÁî´Ï½º Á¶Á÷Àº º¥´õÀÇ ºñÁî´Ï½º Àü·«°ú Á¦Ç° ¸¸Á·µµ¸¦ ±â¹ÝÀ¸·Î Æò°¡ÇÏ¿© ¸ñÇ¥¿¡ ºÎÇÕÇÏ´Â Á¤º¸¿¡ ÀÔ°¢ÇÑ ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖÀ¸¸ç, 4°³ÀÇ »çºÐ¸éÀ¸·Î º¥´õ¸¦ ¸íÈ®Çϰí Á¤È®ÇÏ°Ô ¼¼ºÐÈ­ÇÏ¿© Àü·«Àû ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê¿Í ¼Ö·ç¼ÇÀ» ½Äº°ÇÒ ¼ö ÀÖ½À´Ï´Ù. Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê¿Í ¼Ö·ç¼ÇÀ» ½Äº°ÇÒ ¼ö ÀÖ½À´Ï´Ù.

ÀÓÇöõÆ® ÁÖÀ§¿° ½ÃÀå¿¡¼­ ¼º°øÇϱâ À§ÇÑ Àü·« ºÐ¼® ¹× Ãßõ ÀÓÇöõÆ® ÁÖÀ§¿° ½ÃÀå¿¡¼­ÀÇ ¼º°ø °æ·Î¸¦ ±×¸®´Ù.

ÀÓÇöõÆ® ÁÖÀ§¿° ½ÃÀåÀÇ Àü·«Àû ºÐ¼®Àº ¼¼°è ½ÃÀå¿¡¼­ ÀÔÁö¸¦ °­È­ÇϰíÀÚ ÇÏ´Â ±â¾÷¿¡°Ô ÇʼöÀûÀÔ´Ï´Ù. ÁÖ¿ä ÀÚ¿ø, ¿ª·® ¹× ¼º°ú ÁöÇ¥¸¦ °ËÅäÇÔÀ¸·Î½á ±â¾÷Àº ¼ºÀå ±âȸ¸¦ ½Äº°ÇÏ°í °³¼±ÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Á¢±Ù ¹æ½ÄÀ» ÅëÇØ ±â¾÷Àº °æÀï ȯ°æÀÇ µµÀüÀ» ±Øº¹ÇÏ°í »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Ȱ¿ëÇÏ¿© Àå±âÀûÀÎ ¼º°øÀ» °ÅµÑ ¼ö Àִ ü°è¸¦ ±¸ÃàÇÒ ¼ö ÀÖ½À´Ï´Ù.

ÀÌ º¸°í¼­´Â ÁÖ¿ä °ü½É ºÐ¾ß¸¦ Æ÷°ýÇÏ´Â ½ÃÀå¿¡ ´ëÇÑ Á¾ÇÕÀûÀÎ ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.

1. ½ÃÀå ħÅõµµ : ÇöÀç ½ÃÀå ȯ°æÀÇ »ó¼¼ÇÑ °ËÅä, ÁÖ¿ä ±â¾÷ÀÇ ±¤¹üÀ§ÇÑ µ¥ÀÌÅÍ, ½ÃÀå µµ´Þ ¹üÀ§ ¹× Àü¹ÝÀûÀÎ ¿µÇâ·Â Æò°¡.

2. ½ÃÀå °³Ã´µµ: ½ÅÈï ½ÃÀå¿¡¼­ÀÇ ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇϰí, ±âÁ¸ ºÐ¾ßÀÇ È®Àå °¡´É¼ºÀ» Æò°¡Çϸç, ¹Ì·¡ ¼ºÀåÀ» À§ÇÑ Àü·«Àû ·Îµå¸ÊÀ» Á¦°øÇÕ´Ï´Ù.

3. ½ÃÀå ´Ù°¢È­ : ÃÖ±Ù Á¦Ç° Ãâ½Ã, ¹Ì°³Ã´ Áö¿ª, ¾÷°èÀÇ ÁÖ¿ä ¹ßÀü, ½ÃÀåÀ» Çü¼ºÇÏ´Â Àü·«Àû ÅõÀÚ¸¦ ºÐ¼®ÇÕ´Ï´Ù.

4. °æÀï Æò°¡ ¹× Á¤º¸ : °æÀï ±¸µµ¸¦ öÀúÈ÷ ºÐ¼®ÇÏ¿© ½ÃÀå Á¡À¯À², »ç¾÷ Àü·«, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÀÎÁõ, ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎ, ƯÇã µ¿Çâ, ÁÖ¿ä ±â¾÷ÀÇ ±â¼ú ¹ßÀü µîÀ» °ËÅäÇÕ´Ï´Ù.

5. Á¦Ç° °³¹ß ¹× Çõ½Å : ¹Ì·¡ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ÷´Ü ±â¼ú, ¿¬±¸ °³¹ß Ȱµ¿ ¹× Á¦Ç° Çõ½ÅÀ» °­Á¶ÇÕ´Ï´Ù.

ÀÌÇØ°ü°èÀÚµéÀÌ ÃæºÐÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖµµ·Ï ´ÙÀ½°ú °°Àº Áß¿äÇÑ Áú¹®¿¡ ´ëÇÑ ´äº¯µµ Á¦°øÇÕ´Ï´Ù.

1. ÇöÀç ½ÃÀå ±Ô¸ð¿Í ÇâÈÄ ¼ºÀå Àü¸ÁÀº?

2. ÃÖ°íÀÇ ÅõÀÚ ±âȸ¸¦ Á¦°øÇÏ´Â Á¦Ç°, ºÎ¹®, Áö¿ªÀº?

3. ½ÃÀåÀ» Çü¼ºÇÏ´Â ÁÖ¿ä ±â¼ú µ¿Çâ°ú ±ÔÁ¦ÀÇ ¿µÇâÀº?

4. ÁÖ¿ä º¥´õÀÇ ½ÃÀå Á¡À¯À²°ú °æÀï Æ÷Áö¼ÇÀº?

5.º¥´õ ½ÃÀå ÁøÀÔ ¹× ö¼ö Àü·«ÀÇ ¿øµ¿·ÂÀÌ µÇ´Â ¼öÀÍ¿ø°ú Àü·«Àû ±âȸ´Â ¹«¾ùÀΰ¡?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ½ÃÀå °³¿ä

Á¦5Àå ½ÃÀå ÀλçÀÌÆ®

  • ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀÎ
    • ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ±âȸ
    • °úÁ¦
  • ½ÃÀå ¼¼ºÐÈ­ ºÐ¼®
  • PorterÀÇ Five Forces ºÐ¼®
  • PESTLE ºÐ¼®
    • Á¤Ä¡
    • °æÁ¦
    • »çȸ
    • ±â¼ú
    • ¹ý·ü
    • ȯ°æ

Á¦6Àå ÀÓÇöõÆ® ÁÖÀ§¿° ½ÃÀå : À¯Çüº°

  • ºñ¿Ü°úÀû
    • Ç×»ýÁ¦
    • ·¹ÀÌÀú Á¦°Å
    • ±â°èÀû Á¦°Å
  • ¿Ü°ú ¼ö¼ú
    • »À Àç»ý
    • ÀÓÇöõÆ® ¼ºÇü¼ú
    • Open Flap Debridement

Á¦7Àå ÀÓÇöõÆ® ÁÖÀ§¿° ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº°

  • Ä¡°úÀÇ¿ø
  • º´¿ø

Á¦8Àå ¾Æ¸Þ¸®Ä«ÀÇ ÀÓÇöõÆ® ÁÖÀ§¿° ½ÃÀå

  • ¾Æ¸£ÇîÆ¼³ª
  • ºê¶óÁú
  • ij³ª´Ù
  • ¸ß½ÃÄÚ
  • ¹Ì±¹

Á¦9Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ÀÓÇöõÆ® ÁÖÀ§¿° ½ÃÀå

  • È£ÁÖ
  • Áß±¹
  • Àεµ
  • Àεµ³×½Ã¾Æ
  • ÀϺ»
  • ¸»·¹À̽þÆ
  • Çʸ®ÇÉ
  • ½Ì°¡Æ÷¸£
  • Çѱ¹
  • ´ë¸¸
  • ű¹
  • º£Æ®³²

Á¦10Àå À¯·´, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ ÀÓÇöõÆ® ÁÖÀ§¿° ½ÃÀå

  • µ§¸¶Å©
  • ÀÌÁýÆ®
  • Çɶõµå
  • ÇÁ¶û½º
  • µ¶ÀÏ
  • À̽º¶ó¿¤
  • ÀÌÅ»¸®¾Æ
  • ³×´ú¶õµå
  • ³ªÀÌÁö¸®¾Æ
  • ³ë¸£¿þÀÌ
  • Æú¶õµå
  • īŸ¸£
  • ·¯½Ã¾Æ
  • »ç¿ìµð¾Æ¶óºñ¾Æ
  • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
  • ½ºÆäÀÎ
  • ½º¿þµ§
  • ½ºÀ§½º
  • ÅÍŰ
  • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
  • ¿µ±¹

Á¦11Àå °æÀï ±¸µµ

  • ½ÃÀå Á¡À¯À² ºÐ¼®, 2023
  • FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º, 2023
  • °æÀï ½Ã³ª¸®¿À ºÐ¼®
  • Àü·« ºÐ¼®°ú Á¦¾È

±â¾÷ ¸®½ºÆ®

  • 3M Company
  • Aetna Inc.
  • Basic Pharma Life Science Pvt Ltd.
  • botiss biomaterials GmbH
  • Dawood & Tanner by Dentex Manco Limited
  • Geistlich Pharma AG
  • Healthy Life Pharma Pvt. Ltd.
  • Jiangsu Yenssen Biotech Co., Ltd.
  • Neoss Limited
  • Pfizer Inc.
  • Prachi Pharmaceuticals Private Limited.
  • Silveraid S.r.l.
  • Small Lab Co., Ltd.
  • Straumann Group
  • vVARDIS AG
LSH

The Peri-implantitis Market was valued at USD 956.71 million in 2023, expected to reach USD 1,050.04 million in 2024, and is projected to grow at a CAGR of 9.84%, to USD 1,846.54 million by 2030.

Peri-implantitis, an inflammatory condition affecting the tissues around dental implants, poses significant challenges in the field of dentistry, driven by increasing implant procedures due to aging populations and rising awareness of oral health. Its definition covers inflammation leading to bone loss, endangering implant stability. The necessity for addressing peri-implantitis lies in its potential to compromise the longevity of dental implants, necessitating robust prevention, diagnostic, and treatment applications. These applications encompass antimicrobial therapies, mechanical debridement, and regenerative techniques. End-users span dental clinics, hospitals, and research institutions, highlighting the diversified demand across healthcare settings. Market growth is influenced by factors like advancing dental technologies, increasing patient inclination towards aesthetic dental solutions, and substantial investments in R&D. Opportunities emerge particularly in developing innovative treatment modalities and regenerative solutions, along with personalized medicine approaches utilizing genetic and microbiomic insights. Dental professionals also push for advanced diagnostic tools for early detection, which presents a growing niche for market expansion. However, market limitations include high treatment costs, inadequate insurance coverage, and a lack of standardized treatment protocols, which hamper widespread adoption. Other challenging factors involve the complexity of diagnosing peri-implantitis accurately and effectively treating advanced cases. Innovation is crucial in areas like biomaterial development for more responsive implants, nanotechnology for enhanced antimicrobial surfaces, and machine learning for predictive diagnostics. The market's nature remains highly dynamic, with significant potential in interdisciplinary collaborations bringing together dentistry, biotechnology, and materials science. Firms should focus on strategic partnerships, continuous education for practitioners, and investing heavily in R&D to stay ahead. Successfully navigating these dimensions could lead to significant market penetration and leadership in peri-implantitis treatment solutions.

KEY MARKET STATISTICS
Base Year [2023] USD 956.71 million
Estimated Year [2024] USD 1,050.04 million
Forecast Year [2030] USD 1,846.54 million
CAGR (%) 9.84%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Peri-implantitis Market

The Peri-implantitis Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of peri-implantitis
    • Burgeoning population prone to smoking and diabetes
    • Rise in elderly populace coupled with increasing dental implants
  • Market Restraints
    • Lack of knowledge and cost linked with surgery
  • Market Opportunities
    • Technological innovation and advancements such as laser decontamination
  • Market Challenges
    • Clinical limitations and functional challenges

Porter's Five Forces: A Strategic Tool for Navigating the Peri-implantitis Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Peri-implantitis Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Peri-implantitis Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Peri-implantitis Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Peri-implantitis Market

A detailed market share analysis in the Peri-implantitis Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Peri-implantitis Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Peri-implantitis Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Peri-implantitis Market

A strategic analysis of the Peri-implantitis Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Peri-implantitis Market, highlighting leading vendors and their innovative profiles. These include 3M Company, Aetna Inc., Basic Pharma Life Science Pvt Ltd., botiss biomaterials GmbH, Dawood & Tanner by Dentex Manco Limited, Geistlich Pharma AG, Healthy Life Pharma Pvt. Ltd., Jiangsu Yenssen Biotech Co., Ltd., Neoss Limited, Pfizer Inc., Prachi Pharmaceuticals Private Limited., Silveraid S.r.l., Small Lab Co., Ltd., Straumann Group, and vVARDIS AG.

Market Segmentation & Coverage

This research report categorizes the Peri-implantitis Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Non-Surgical and Surgical. The Non-Surgical is further studied across Antibiotics, Laser Debridement, and Mechanical Debridement. The Surgical is further studied across Bone Regeneration, Implanto-Plasty, and Open Flap Debridement.
  • Based on End-User, market is studied across Dental Clinics and Hospitals.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of peri-implantitis
      • 5.1.1.2. Burgeoning population prone to smoking and diabetes
      • 5.1.1.3. Rise in elderly populace coupled with increasing dental implants
    • 5.1.2. Restraints
      • 5.1.2.1. Lack of knowledge and cost linked with surgery
    • 5.1.3. Opportunities
      • 5.1.3.1. Technological innovation and advancements such as laser decontamination
    • 5.1.4. Challenges
      • 5.1.4.1. Clinical limitations and functional challenges
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Peri-implantitis Market, by Type

  • 6.1. Introduction
  • 6.2. Non-Surgical
    • 6.2.1. Antibiotics
    • 6.2.2. Laser Debridement
    • 6.2.3. Mechanical Debridement
  • 6.3. Surgical
    • 6.3.1. Bone Regeneration
    • 6.3.2. Implanto-Plasty
    • 6.3.3. Open Flap Debridement

7. Peri-implantitis Market, by End-User

  • 7.1. Introduction
  • 7.2. Dental Clinics
  • 7.3. Hospitals

8. Americas Peri-implantitis Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Peri-implantitis Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Peri-implantitis Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. 3M Company
  • 2. Aetna Inc.
  • 3. Basic Pharma Life Science Pvt Ltd.
  • 4. botiss biomaterials GmbH
  • 5. Dawood & Tanner by Dentex Manco Limited
  • 6. Geistlich Pharma AG
  • 7. Healthy Life Pharma Pvt. Ltd.
  • 8. Jiangsu Yenssen Biotech Co., Ltd.
  • 9. Neoss Limited
  • 10. Pfizer Inc.
  • 11. Prachi Pharmaceuticals Private Limited.
  • 12. Silveraid S.r.l.
  • 13. Small Lab Co., Ltd.
  • 14. Straumann Group
  • 15. vVARDIS AG
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦